Monopar Therapeutics (NASDAQ:MNPR) Given Overweight Rating at Cantor Fitzgerald

Key Points

• Cantor Fitzgerald has reiterated an "overweight" rating for Monopar Therapeutics, with a price target of $74.00, indicating a potential upside of 131.03% from its previous closing price.
• Five analysts have rated Monopar with a "Buy," and one has a "Hold," leading to a consensus rating of "Moderate Buy" and a target price of $66.00.
• The company's stock has shown a significant movement, closing at $32.03 with a 12-month high of $54.30 and a 5.3% increase recently.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report)'s stock had its "overweight" rating reiterated by Cantor Fitzgerald in a report released on Wednesday,Benzinga reports. They presently have a $74.00 price objective on the stock. Cantor Fitzgerald's price target points to a potential upside of 131.03% from the stock's previous close.

Several other analysts also recently issued reports on MNPR. HC Wainwright assumed coverage on Monopar Therapeutics in a report on Tuesday. They issued a "buy" rating and a $70.00 price target for the company. Chardan Capital reissued a "buy" rating and set a $60.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, August 13th. Finally, Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, May 22nd. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Monopar Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $66.00.

Monopar Therapeutics Trading Up 5.3%

MNPR stock opened at $32.03 on Wednesday. The firm has a 50 day moving average of $37.77 and a 200-day moving average of $37.16. The company has a market cap of $197.63 million, a price-to-earnings ratio of -9.62 and a beta of 1.05. Monopar Therapeutics has a 12-month low of $2.25 and a 12-month high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. Sell-side analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Christopher M. Starr sold 16,800 shares of the business's stock in a transaction dated Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the sale, the director directly owned 5,173 shares of the company's stock, valued at $206,920. The trade was a 76.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the chief executive officer owned 73,472 shares in the company, valued at $2,938,880. The trade was a 18.61% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Monopar Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC bought a new position in Monopar Therapeutics in the 4th quarter worth about $23,435,000. RA Capital Management L.P. bought a new stake in shares of Monopar Therapeutics in the 4th quarter worth approximately $11,247,000. Point72 Asset Management L.P. bought a new stake in Monopar Therapeutics during the 4th quarter valued at approximately $3,694,000. Affinity Asset Advisors LLC bought a new stake in shares of Monopar Therapeutics during the first quarter valued at approximately $2,257,000. Finally, Geode Capital Management LLC boosted its holdings in shares of Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock valued at $3,468,000 after buying an additional 48,379 shares in the last quarter. Institutional investors own 1.83% of the company's stock.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.